phenylalanine has been researched along with rosiglitazone in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Füchtenbusch, M; Schatz, H; Standl, E | 1 |
| Göke, B; Parhofer, KG | 1 |
| Anglard, P; Bonnafous, S; Chavey, C; Mari, B; Monthouel, MN; Tartare-Deckert, S; Van Obberghen, E | 1 |
| Foley, JE; Fonseca, V; Grunberger, G; Gupta, S; Shen, S | 1 |
| Tesz, G; Zawalich, KC; Zawalich, WS | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Bell, D; McDermott, BJ | 1 |
| Abdel-Salam, OM; Baiuomy, AR; El-Batran, SA; Nofal, SM | 1 |
| Freudlsperger, C; Kaltschmidt, C; Kompisch, K; Lorke, DE; Lukacs, Z; Müller, R; Rudolph, T; Santer, R; Schulz, D; Schumacher, U; Ullrich, K | 1 |
| Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L | 1 |
| Kalliokoski, A; Neuvonen, PJ; Niemi, M | 1 |
3 review(s) available for phenylalanine and rosiglitazone
| Article | Year |
|---|---|
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
SLCO1B1 polymorphism and oral antidiabetic drugs.
Topics: Administration, Oral; Alleles; Carbamates; Cyclohexanes; Genotype; Haplotypes; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Nateglinide; Organic Anion Transporters; Phenylalanine; Pioglitazone; Piperidines; Polymorphism, Genetic; Rosiglitazone; Thiazolidinediones | 2010 |
1 trial(s) available for phenylalanine and rosiglitazone
| Article | Year |
|---|---|
Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Rosiglitazone; Safety; Single-Blind Method; Thiazolidinediones; Time Factors | 2003 |
7 other study(ies) available for phenylalanine and rosiglitazone
| Article | Year |
|---|---|
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.
Topics: Adipocytes; Animals; Blood Vessels; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Diet; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Male; Matrix Metalloproteinase 12; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Matrix Metalloproteinases, Membrane-Associated; Matrix Metalloproteinases, Secreted; Metalloendopeptidases; Mice; Mice, Inbred AKR; Mice, Inbred C57BL; Mice, Obese; Mitosis; Obesity; Phenylalanine; Protease Inhibitors; RNA, Messenger; Rosiglitazone; Stromal Cells; Thiazoles; Thiazolidinediones; Thiophenes; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-3 | 2003 |
Contrasting effects of nateglinide and rosiglitazone on insulin secretion and phospholipase C activation.
Topics: Androstadienes; Animals; Chromans; Cyclohexanes; Enzyme Activation; Glucose; Hypoglycemic Agents; Indicators and Reagents; Inositol Phosphates; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Perfusion; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone; Type C Phospholipases; Wortmannin | 2003 |
Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy.
Topics: Animals; Cell Survival; Cells, Cultured; Culture Media; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Drug Interactions; Endothelin-1; Glucose; Heart Ventricles; Hypertrophy; Insulin; Insulin-Like Growth Factor I; Isoproterenol; Male; Myocytes, Cardiac; Norepinephrine; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazolidinediones | 2005 |
Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Cholesterol; Cyclohexanes; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Metformin; Nateglinide; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
High concentrations of phenylalanine stimulate peroxisome proliferator-activated receptor gamma: implications for the pathophysiology of phenylketonuria.
Topics: Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation; Humans; Immunohistochemistry; Microarray Analysis; Neuroblastoma; Neurons; Phenylalanine; Phenylketonurias; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones | 2009 |